Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVS

Novartis AG ADR

Dec 01 • 04:00PM ET

98.13

Dollar change +0.23
Percentage change 0.23	%

Healthcare • Drug Manufacturers - General • Switzerland • NYSE

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	26.41	EPS (ttm)	3.72	Insider Own	0.00%	Shs Outstand	2.12B	Perf Week	-0.01%
Market Cap	195.61B	Forward P/E	13.81	EPS next Y	7.10	Insider Trans	-	Shs Float	1.99B	Perf Month	4.11%
Income	7.83B	PEG	3.53	EPS next Q	1.58	Inst Own	7.54%	Short Float / Ratio	0.19% / 2.56	Perf Quarter	2.96%
Sales	51.01B	P/S	3.83	EPS this Y	12.83%	Inst Trans	-8.85%	Short Interest	3.84M	Perf Half Y	4.84%
Book/sh	18.57	P/B	5.29	EPS next Y	8.54%	ROA	6.56%	Target Price	108.37	Perf Year	15.79%
Cash/sh	6.37	P/C	15.41	EPS next 5Y	7.49%	ROE	15.32%	52W Range	75.68 - 99.94	Perf YTD	14.31%
Dividend	3.55	P/FCF	13.04	EPS past 5Y	-0.56%	ROI	13.58%	52W High	-1.81%	Beta	0.56
Dividend %	3.62%	Quick Ratio	0.83	Sales past 5Y	0.74%	Gross Margin	70.03%	52W Low	29.66%	ATR	1.11
Employees	101703	Current Ratio	0.94	Sales Q/Q	-6.15%	Oper. Margin	25.65%	RSI (14)	63.00	Volatility	0.81% 0.87%
Optionable	Yes	Debt/Eq	0.66	EPS Q/Q	17.03%	Profit Margin	15.35%	Rel Volume	0.79	Prev Close	97.90
Shortable	Yes	LT Debt/Eq	0.51	Earnings	Oct 24 BMO	Payout	71.32%	Avg Volume	1.50M	Price	98.13
Recom	2.46	SMA20	3.10%	SMA50	2.68%	SMA200	5.51%	Volume	1,187,807	Change	0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform
Sep-14-22	Downgrade	Berenberg	Buy → Hold
May-09-22	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-10-22	Resumed	Citigroup	Buy
Dec-14-21	Downgrade	Redburn	Buy → Neutral
Dec-06-21	Downgrade	Exane BNP Paribas	Outperform → Neutral
Dec-03-21	Downgrade	Bryan Garnier	Buy → Neutral
Sep-20-21	Downgrade	Deutsche Bank	Hold → Sell
Mar-22-21	Initiated	Bernstein	Mkt Perform
Mar-10-21	Downgrade	Argus	Buy → Hold
Feb-01-21	Downgrade	Cowen	Outperform → Market Perform	$110 → $105
Jan-15-21	Initiated	Deutsche Bank	Buy
Sep-29-20	Initiated	Berenberg	Buy
Sep-10-20	Upgrade	UBS	Neutral → Buy

Show Previous Ratings

Nov-30-23 04:36PM	25 Most Expensive Countries in the World to Raise a Child (Insider Monkey)
04:10PM	Analyst Report: Novartis AG (Morningstar Research)
Nov-29-23 10:30AM	Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies (Benzinga)
Nov-28-23 02:48PM	Analyst Report: Novartis AG (Morningstar Research)
12:52PM	Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy (Zacks)
10:46AM	Loading…
10:46AM	FDA investigating cancer risk linked to CAR-T cell therapy (BioPharma Dive)
10:36AM	Novartis: CEO needs to convince over long-term prospects (Financial Times)
10:17AM	Novartis bought his first startup for $3.9 billion. Now this physicist is trying to sell Europe on a new generation of nuclear energy (Fortune)
07:00AM	Novartis sees brighter sales future as R&D revamp continues (BioPharma Dive)
02:37AM	Novartis Raises Mid-Term Sales Growth Targets (The Wall Street Journal)
01:00AM	Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day (GlobeNewswire)
Nov-26-23 03:11PM	12 Best Diabetes Stocks To Buy Now (Insider Monkey)
Nov-20-23 11:09PM	Q3 2023 Legend Biotech Corp Earnings Call (Thomson Reuters StreetEvents)
06:52AM	20 Most Valuable Healthcare Companies in the World (Insider Monkey)
01:15AM	Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH (GlobeNewswire)
08:45AM	Loading…
Nov-14-23 08:45AM	Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030 (PR Newswire)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
10:02AM	Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment (FierceBiotech.com)
07:00AM	Novartis licenses Legend cell therapy for lung cancer (BioPharma Dive)
Nov-09-23 11:00AM	Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 (GlobeNewswire)
Nov-05-23 10:00AM	3 Spectacular High-Yield Dividend Stocks to Buy in November (Motley Fool)
Nov-03-23 11:47AM	Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues (Zacks)
Nov-01-23 08:30AM	Get Ready for Next Generation of Diabetes, Weight-Management Drugs (PR Newswire)
Oct-31-23 04:50PM	FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade (GlobeNewswire)
12:14PM	Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates (Zacks)
Oct-30-23 07:11AM	Novartis' $3.2B Chinook bet takes flight as phase 3 hits endpoint, providing launchpad for 2024 FDA filing (FierceBiotech.com)
07:00AM	Novartis bet on kidney disease drug yields positive study data (BioPharma Dive)
06:30AM	UPDATE 1-Novartis drug candidate scores interim win in rare kidney disease trial (Reuters)
02:15AM	Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) (GlobeNewswire)
Oct-28-23 06:50AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
11:36AM	Loading…
Oct-27-23 11:36AM	Incyte (INCY) to Report Q3 Earnings: What's in the Cards? (Zacks)
10:05AM	Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products (Zacks)
05:05AM	2 Green Flags and 1 Red Flag for Novartis Stock (Motley Fool)
Oct-25-23 11:49AM	Novartis AG (NYSE:NVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-24-23 04:07PM	Novartis Hikes Its Earnings Outlook For The Third Time This Year (Investor's Business Daily)
03:00PM	Novartis Ag (NVS) Q3 2023 Earnings Call Transcript (Motley Fool)
11:24AM	Novartis Expects $1 Billion in Revenue From This Cancer Drug This Year (The Wall Street Journal)
09:30AM	Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:01AM	Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View (Zacks)
06:02AM	ESMO: As peers enter radiopharmaceuticals, Novartis says welcome to the party (FierceBiotech.com)
05:44AM	Novartis Begins New Era With Profit Beat and Guidance Hike. Investors Are Cautious. (Barrons.com)
05:03AM	Novartis: Q3 Earnings Snapshot (Associated Press Finance)
03:17AM	Pharmaceutical industry close to deal with UK on drug pricing, says Novartis (Financial Times)
03:04AM	Novartis Raises Earnings Guidance After Key Drugs Boost Profit, Sales (The Wall Street Journal)
01:11AM	Novartis lifts 2023 earnings forecast for third time (Reuters)
01:00AM	Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance (GlobeNewswire)
Oct-23-23 10:30AM	Novartis Pluvicto shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting (GlobeNewswire)
Oct-20-23 10:20AM	Novartis (NVS) to Report Q3 Earnings: What's in the Offing? (Zacks)
06:00AM	Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer (GlobeNewswire)
Oct-18-23 06:00PM	Novartis (NVS) Stock Moves -0.4%: What You Should Know (Zacks)
Oct-17-23 10:07AM	2 Biotech Stocks That Could Make You Richer (Motley Fool)
05:10AM	3 Unstoppable Stocks to Buy and Hold for Decades (Motley Fool)
Oct-12-23 06:00PM	Novartis (NVS) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-10-23 07:44AM	Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study (Zacks)
Oct-06-23 06:00PM	Novartis (NVS) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
09:30AM	Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates (Zacks)
Oct-05-23 06:15PM	Novartis (NVS) Stock Moves -0.01%: What You Should Know (Zacks)
01:15AM	Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer (GlobeNewswire)
Oct-04-23 06:52PM	Analyst Report: Novartis AG (Morningstar Research)
02:51PM	Stocks to Watch Wednesday: Tesla, Intel, Cal-Maine, Novavax (The Wall Street Journal)
11:47AM	Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook (Zacks)
11:33AM	SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today (InvestorPlace)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
08:21AM	Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio (Zacks)
07:00AM	OTC Markets Group Welcomes Sandoz Group AG to OTCQX (GlobeNewswire)
06:28AM	The Bond and Stock Selloff Has Momentum. Heres How It Could End. (Barrons.com)
04:55AM	UPDATE 2-European stocks slide for third day running as yields march higher (Reuters)
01:28AM	Novartis' Sandoz valued at $11.2 bln in market debut (Reuters)
01:00AM	Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company (GlobeNewswire)
Oct-03-23 05:00PM	Novartis to Complete Spinoff of Generic Drug Division (Barrons.com)
01:10PM	Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO (CNBC TV)
12:08PM	Eli Lilly to buy cancer specialist Point for $1.4bn (Financial Times)
11:50AM	Novartis (NVS) Announces Positive Data on Kidney Disease Drug (Zacks)
10:13AM	Novartis considers selling radiopharma unit's assets - Bloomberg News (Reuters)
10:08AM	The 10 pharma companies participating in Medicare price negotiations (Yahoo Finance Video)
09:56AM	Novartis Weighs Selling Assets from Radiopharma Unit (Bloomberg)
09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
Oct-02-23 10:32AM	Analyst applauds Novartis' 'faultless' iptacopan performance in phase 3 kidney trial (FierceBiotech.com)
10:12AM	Boehringer launches unbranded Humira biosimilar at 81% discount (Reuters)
03:05AM	Novartis offloads ophthalmology assets for $2.5bn (Pharmaceutical Business Review)
01:15AM	Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) (GlobeNewswire)
Sep-29-23 06:00PM	Novartis (NVS) Dips More Than Broader Markets: What You Should Know (Zacks)
10:00AM	Novartis completes divestment of front of eye ophthalmology assets (GlobeNewswire)
09:24AM	Adlai, building on the ashes of Novartis' failure, raises $57.5M IPO to run phase 3 cancer trial (FierceBiotech.com)
Sep-28-23 10:06AM	Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs (Zacks)
Sep-27-23 10:52AM	Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study (Zacks)
09:58AM	Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5% (Zacks)
Sep-26-23 12:26PM	Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar (Zacks)
01:15AM	Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe (GlobeNewswire)
Sep-25-23 12:58PM	Amazon Invests Up To $4B In ChatGPT Competitor, Hollywood Writers Accept Preliminary Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories (Benzinga)
12:12PM	Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study (Zacks)
12:06PM	Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies (Zacks)
12:04PM	FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease (Zacks)
01:17AM	Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (GlobeNewswire)
01:15AM	Novartis confirms Sandoz Spin-off for October 4, 2023 (GlobeNewswire)
Sep-22-23 06:00PM	Novartis (NVS) Dips More Than Broader Markets: What You Should Know (Zacks)
12:00PM	Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study (Zacks)
11:57AM	Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze (Zacks)
Sep-20-23 10:45AM	FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma (Zacks)
Sep-19-23 06:22AM	UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination (Reuters)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVS

Novartis AG ADR

Upgrade your FINVIZ experience